Skip to content
Prescott Bio Canada

Cagrilintide: Research Summary

Published: 2026-08-03 · Last updated: 2026-08-03

Mechanism

Cagrilintide is a long-acting synthetic analog of amylin — the pancreatic beta-cell peptide co-secreted with insulin — engineered for once-weekly subcutaneous dosing via a fatty-acid side chain that binds albumin. It is a dual amylin and calcitonin receptor agonist (DACRA), meaning it activates both amylin receptors (AMY1, AMY2, AMY3 — heterodimers of the calcitonin receptor with RAMP1/2/3) and the calcitonin receptor itself. Downstream effects include slowed gastric emptying, suppressed post-prandial glucagon, and central satiety signaling through hindbrain amylin-responsive neurons. The mechanism is complementary to GLP-1 agonism, which underlies the rationale for co-administration with semaglutide.

Published trials

The most-cited data set is the CagriSema program — fixed-ratio co- administration of cagrilintide and semaglutide 2.4 mg. A Phase 1b trial reported that CagriSema achieved greater body-weight reduction than either agent alone over 20 weeks in participants with type 2 diabetes. Cagrilintide as monotherapy has been evaluated in Phase 2 dose-ranging trials in obesity, with reported weight reductions in the range of 6–10% over 26 weeks depending on dose, alongside favorable tolerability.

The Phase 3 REDEFINE program (obesity) and REIMAGINE program (type 2 diabetes) have been designed around CagriSema. Topline data from REDEFINE-1 (obesity without diabetes) and REDEFINE-2 (obesity with type 2 diabetes) have been reported and are the reference public data sets for CagriSema's clinical profile. Head-to-head comparability with tirzepatide remains an active analytical question.

Safety profile

Cagrilintide's tolerability profile as reported in Phase 1b and Phase 2 studies is dominated by gastrointestinal adverse events (nausea, vomiting, diarrhea) that cluster during dose escalation and typically resolve with continued titration — a pattern shared with amylin analogs and the incretin class. Injection-site reactions are reported at low rates. Long-term controlled human safety data at cardiovascular-outcomes scale is not yet available.

How it compares in its class

Within the amylin analog class, cagrilintide is the long-acting successor to pramlintide (a short-acting amylin analog used adjunctively with insulin). Within the broader weight-management pharmacotherapy landscape, it is the amylin arm of a "combination biologic" strategy that pairs an amylin agonist with a GLP-1 agonist — a mechanistically distinct approach from single-molecule dual (tirzepatide) or triple (retatrutide) incretin agonists. Whether combination CagriSema will match or exceed the tri- agonist Phase 3 numbers is the open comparative question in the field.

References

  • PMID: 34762860 — Enebo LB et al., "Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg." Lancet 2021.
  • PMID: 34793756 — Lau DCW et al., Cagrilintide monotherapy dose-ranging obesity trial. Lancet 2021.
  • DOI: 10.1016/S0140-6736(21)01751-7 — Lancet 2021 CagriSema Phase 1b (Enebo).

Buy Cagrilintide in Canada: Prescott Bio Canada carries Cagrilintide vials — HPLC + mass-spec tested, ships from Richmond BC in 2-4 business days.